<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00650026</url>
  </required_header>
  <id_info>
    <org_study_id>M03-583</org_study_id>
    <nct_id>NCT00650026</nct_id>
  </id_info>
  <brief_title>Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis</brief_title>
  <acronym>ReAct</acronym>
  <official_title>Multicenter Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      Multicenter Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody
      Adalimumab in Subjects with Active Rheumatoid Arthritis
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>40 mg adalimumab every other week</description>
    <other_name>ABT-D2E7</other_name>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eighteen years or older

          -  Females - post-menopausal for at least 1 year, surgically sterile or practicing an
             acceptable method of birth control

          -  Females - negative pregnancy test at screening

          -  Confirmed diagnosis of active RA &gt;= 6 swollen joints and &gt;= 9 tender joints

          -  Met ACR criteria for diagnosis of RA for at least 3 months

          -  Active RA defined by a DAS &gt;= 3.2 at study entry

        Exclusion Criteria:

          -  Subject had prior treatment with cyclophosphamide or chlorambucil

          -  Subjects previously treated with total lymphoid irradiation or anti-CD4 or CAMPATH 1H
             monoclonal antibodies resulting in CD4 lymphopenia

          -  Prior treatment with intravenous immunoglobulin or investigational agent in with 30
             days or 5 half-lives of adalimumab

          -  Subject with history of cancer within the past 10 years other than resected basal cell
             or squamous cell carcinoma of the skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2008</study_first_submitted>
  <study_first_submitted_qc>March 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>April 10, 2008</last_update_submitted>
  <last_update_submitted_qc>April 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Larry McNamee, Sr. Clinical Research Manager</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

